June 16, 2020 / 10:11 AM / 16 days ago

BRIEF-GSK And Ideaya Announce Broad Partnership In Synthetic Lethality

June 16 (Reuters) - GlaxoSmithKline PLC:

* GSK - IDEAYA AND GSK ANNOUNCE A BROAD PARTNERSHIP IN SYNTHETIC LETHALITY, AN EMERGING FIELD IN PRECISION MEDICINE ONCOLOGY

* GSK - IDEAYA WILL RECEIVE A $100 MILLION UPFRONT CASH PAYMENT

* GSK - IDEAYA WILL RECEIVE A 50% US PROFIT SHARE FOR MAT2A AND WERNER HELICASE PROGRAMS

* GSK - PARTNERSHIP COVERS THREE IDEAYA SYNTHETIC LETHALITY PROGRAMS - MAT2A, POL THETA AND WERNER HELICASE Source text : bit.ly/2Be8Eai Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below